S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Authors:

Jennifer E. Amengual

Patrick M. Reagan

H. Li

Hayder Saeed

Riha Vaidya

Joseph M. Unger

Alexey V. Danilov

Michael LeBlanc

Jonathan W. Friedberg

Sonali M. Smith

Affiliated Authors: